Paclitaxel and Corneal opacity - a phase IV clinical study of FDA data

Summary:

Corneal opacity is reported only by a few people who take Paclitaxel.

The phase IV clinical study analyzes which people take Paclitaxel and have Corneal opacity. It is created by eHealthMe based on reports of 67,485 people who have side effects while taking Paclitaxel from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

67,485 people reported to have side effects when taking Paclitaxel.
Among them, 2 people (0.0%) have Corneal opacity.

What is Paclitaxel?

Paclitaxel has active ingredients of paclitaxel. It is often used in breast cancer. eHealthMe is studying from 67,558 Paclitaxel users for its effectiveness, alternative drugs and more.

What is Corneal opacity?

Corneal opacity (scarring or clouding of the cornea) is found to be associated with 567 drugs and 285 conditions by eHealthMe.

Number of Paclitaxel and Corneal opacity reports submitted per year:

Gender of people who have Corneal opacity when taking Paclitaxel *:

female: 50 %
male: 50 %

Age of people who have Corneal opacity when taking Paclitaxel *:

Common drugs people take besides Paclitaxel *:

Common side effects people have besides Corneal opacity *:

Ulcerative Keratitis (ulcerative inflammation of the cornea): 2 people, 100.00%
Retinopathy (acute damage to the retina of the eye): 2 people, 100.00%
Keratitis (eye's cornea, the front part of the eye, becomes inflamed): 2 people, 100.00%
White Blood Cell Count Decreased: 1 person, 50.00%
Hepatic Function Abnormal: 1 person, 50.00%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 50.00%
Ards (Acute Respiratory Distress Syndrome) (sudden failure of the respiratory (breathing) system): 1 person, 50.00%
Bacteraemia (presence of bacteria in the blood): 1 person, 50.00%
Bleeding Disorders: 1 person, 50.00%
Bone Marrow Failure: 1 person, 50.00%

Common conditions people have *:

Lung Cancer - Non-Small Cell (lung cancer): 2 people, 100.00%
Iron Overload: 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Paclitaxel and have Corneal opacity?

Check whether Corneal opacity is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Corneal opacity and when was it recovered:

Corneal opacity in Paclitaxel

Expand to all the drugs that have ingredients of paclitaxel:

Corneal opacity and drugs with ingredients of paclitaxel

Alternative drugs to, pros and cons of Paclitaxel:

Paclitaxel (67,558 reports)

Common Paclitaxel side effects:

Browse all side effects of Paclitaxel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Corneal opacity treatments and more:

Corneal opacity (1,413 reports)

COVID vaccines that are related to Corneal opacity:

All the drugs that are associated with Corneal opacity:

Corneal opacity (567 drugs)

All the conditions that are associated with Corneal opacity:

Corneal opacity (285 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paclitaxel (the active ingredients of Paclitaxel) and Paclitaxel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.